Tissue-regeneration company Isolagen Inc. brought in $59.5 million in a follow-on offering Thursday, leaving it with wrinkle-free plans to begin pivotal trials and bring its lead anti-aging product to the market. (BioWorld Today)
As it transforms itself from a genomics discovery company to a product development company, CuraGen Corp. in-licensed a promising cancer compound from the Danish firm TopoTarget A/S. (BioWorld Today)
In spite of an FDA panel's recommendation against Allos Therapeutics Inc.'s RSR13, the agency issued an approvable letter for the radiation sensitizer. (BioWorld Today)
Breathing a sigh of satisfaction after years of hard work, officials at Indevus Pharmaceuticals Inc. reached a long-awaited milestone on Friday with the FDA approval of Sanctura. (BioWorld Today)
